DownRightNowNews
Trending
Apple Challenges UK Secrecy Over iCloud Encryption OrderCNN Analysis: GOP produced 500+ ads. Only 12 that aired were about TrumpRFK, Jr. ‘looking at chemtrails,’ a debunked conspiracy theorySept. 17: F-16 pilot ejects, flames shoot from plane engineRs 40 lakh home loan: The EMI looks cheaper at 30 years, but there’s a costly catch, warns CAAll-out war at Bombay House: Trusts calls Chandra's return 'illegal,' Noel fights to keep Tata Sons unlistedMissing in Election Commission affidavit: Break-up of Bengal SIR appeals for inclusion, exclusion of namesDecomposed body found in open field: 16-year-old gangraped, killed; three minors apprehendedApple Challenges UK Secrecy Over iCloud Encryption OrderCNN Analysis: GOP produced 500+ ads. Only 12 that aired were about TrumpRFK, Jr. ‘looking at chemtrails,’ a debunked conspiracy theorySept. 17: F-16 pilot ejects, flames shoot from plane engineRs 40 lakh home loan: The EMI looks cheaper at 30 years, but there’s a costly catch, warns CAAll-out war at Bombay House: Trusts calls Chandra's return 'illegal,' Noel fights to keep Tata Sons unlistedMissing in Election Commission affidavit: Break-up of Bengal SIR appeals for inclusion, exclusion of namesDecomposed body found in open field: 16-year-old gangraped, killed; three minors apprehended
Science

Dualitas Therapeutics and Roche Partner to Discover Bispecific Antibodies for I&I Diseases

·1h ago
Share:PostShare

Dualitas Therapeutics has announced a research collaboration and licence agreement with Roche to discover and develop novel bispecific antibody (BsAb) therapies for immunology and inflammation (I&I) diseases. The DualScreenTM platform is designed to support high-throughput discovery of bispecific antibodies based on proximity biology. Unlike conventional approaches that typically begin with selected target pairs, the platform evaluates a broad range of targets and epitopes

P

Pharmaceutical Tech

Original source

Read full story

discover

Check live status on DownRightNow

Check status →
HealthTechnologySports

Related Stories

Science13h ago

ViiV Healthcare Partners with Prevention Access Campaign (PAC) to Celebrate 10 Years of U=U and Look to The Future

DURHAM, N.C.--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced the continuation of its long-standing partnership with Prevention Access Campaign (PAC) – the founding organization behind the Undetectable = Untransmittable (U=U) movement. To celebrate 10 years of U=U, ViiV Healthcare is joining PAC to introduce “Undetectable Voices,” a new digital storytelling and community engagement campaign that builds on

BBusinesswire

Headlines and briefs on this site are for information only. Always verify details on the original source or live status page.

Read Disclaimer